MYRIAD GENETICS INC — Director's Dealing 2015

Jul 2, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2015-07-01

Reporting Person: Wenstrup Richard (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$16.53	2020-09-15	Common Stock (808)		Direct
Incentive Stock Option (right to buy)	$18.0	2021-02-23	Common Stock (3750)		Direct
Incentive Stock Option (right to buy)	$19.47	2021-09-13	Common Stock (1669)		Direct
Incentive Stock Option (right to buy)	$23.98	2022-03-07	Common Stock (1500)		Direct
Incentive Stock Option (right to buy)	$26.49	2021-09-17	Common Stock (3775)		Direct
Incentive Stock Option (right to buy)	$27.07	2022-09-12	Common Stock (2365)		Direct
Non-Qualified Stock Option (right to buy)	$16.53	2020-09-15	Common Stock (14192)		Direct
Non-Qualified Stock Option (right to buy)	$18.0	2021-02-23	Common Stock (10250)		Direct
Non-Qualified Stock Option (right to buy)	$19.47	2021-09-13	Common Stock (20331)		Direct
Non-Qualified Stock Option (right to buy)	$23.98	2022-03-07	Common Stock (4500)		Direct
Non-Qualified Stock Option (right to buy)	$26.49	2021-09-17	Common Stock (23725)		Direct
Non-Qualified Stock Option (right to buy)	$27.07	2022-09-12	Common Stock (22635)		Direct

Footnotes

F1: Vests 25% a year over four years - initial vesting 9/13/12, final vesting 9/13/15

F2: Vests 25% a year over four years - initial vesting 3/7/13, final vesting 3/7/16

F3: Vests 25% a year over four years - initial vesting 9/17/14, final vesting 9/17/17

F4: Vests 25% a year over four years - initial vesting 9/12/13, final vesting 9/12/16